Korean J Urol.  2007 Aug;48(8):809-814. 10.4111/kju.2007.48.8.809.

Pathologic Characteristics of Prostate Cancers Missed by Application of the Age-specific Prostate-specific Antigen Reference in Men over Sixties

• Jeong SJ
• Han JH
• Chang IH
• Yu JH
• Han BK
• Hong SK
• Byun SS
• Lee SE

• KMID: 2061274
• DOI: http://doi.org/10.4111/kju.2007.48.8.809

Abstract

PURPOSE
To examine the pathologic characteristics of prostate cancers missed by application of the age-specific prostate-specific antigen(PSA) reference in Korean men over sixties in clinical practice based on PSA cutoff 3.0ng/ml.
MATERIALS AND METHODS
We made retrospective analysis of 1,063 patients aged between 60-79 who had had transrectal ultrasonography(TRUS)- guided biopsy due to the rise of PSA over 3.0ng/ml or abnormal findings in digital rectal examination(DRE) or TRUS. Age-specific PSA reference was set at 3.9ng/ml for 60s and 5.4ng/ml for 70s.
RESULTS
Prostate cancer was detected in 34.3%(365/1,063) as a whole, and 31.5% in 60s, and 39.5% in 70s according to the age. When age-specific reference 3.9ng/ml was applied to 60s, 20(9.6%) cancers were missed compared with clinical cutoff value(3.0ng/ml). When age-specific reference 5.4ng/ml was applied to 70s, 23(16.0%) cancers were missed. On the average, 43(12.2%) of cancers were missed in 60s and 70s. Of 43 missed cancers, 39(90.7%) were with normal DRE and TRUS. Of these cancers, 16(41.0%) were clinically insignificant on biopsy, but only 7(22.6%) were insignificant in the pathologic examination of 31 radical prostatectomy specimens.
CONCLUSIONS
In our clinical practice based on PSA cutoff 3.0ng/ml, most cancers missed by application of age-specific reference are clinically significant. But, considering the positive effect of age-specific reference on avoidance of unnecessary biopsies, large prospective study is needed to evaluate the efficacy of age-specific reference in Korean men over sixties.

Keyword

Prostate cancer; Prostate-specific antigen; Age

MeSH Terms

Biopsy
Humans
Male
Prostate*
Prostate-Specific Antigen*
Prostatectomy
Prostatic Neoplasms*
Retrospective Studies
Prostate-Specific Antigen

Reference

1. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol. 1995. 153:1160–1163.

2. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993. 270:860–864.

3. Lee SE, Kwak C, Park MS, Lee CH, Kang W, Oh SJ. Ethnic differences in the age-related distribution of serum prostate-specific antigen values: a study in a healthy Korean male population. Urology. 2000. 56:1007–1010.

4. Choi YD, Hong SJ, Rha KH, Kim BH, Cha KB, Song JS, et al. Age-specific reference ranges for serum prostate-specific antigen: community-based survey in Namhae region. Korean J Urol. 2001. 42:834–839.

5. Jeon HJ, Kim YS, Kang DR, Nam CM, Kim CI, Seong DH, et al. Age-specific reference ranges for serum prostate- specific antigen in Korean men. Korean J Urol. 2006. 47:586–590.

6. Collins GN, Lee RJ, McKelvie GB, Rogers AC, Hehir M. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol. 1993. 71:445–450.

7. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994. 152:2037–2042.

8. Ku JH, Ahn JO, Lee CH, Lee NK, Park YH, Byun SS, et al. Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity. Urology. 2002. 60:475–479.

9. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0ng per milliliter. N Engl J Med. 2004. 350:2239–2246.

10. Park HK, Hong SK, Byun SS, Lee SE. Comparison of the rate of detecting prostate cancer and the pathologic characteristics of the patients with a serum PSA level in the range of 3.0 to 4.0ng/ml and the patients with a serum PSA level in the range 4.1 to 10.0ng/ml. Korean J Urol. 2006. 47:358–361.

11. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol. 2001. 166:104–110.

12. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol. 2003. 170:370–372.

13. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991. 324:1156–1161.

14. Speights VO Jr, Brawn PN, Foster DM, Spiekerman AM, Kuhl D, Riggs MW. Evaluation of age-specific normal ranges for prostate-specific antigen. Urology. 1995. 45:454–457.

15. Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, Oesterling JE. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. J Urol. 1996. 155:1336–1339.

16. Borer JG, Sherman J, Solomon MC, Plawker MW, Macchia RJ. Age specific prostate specific antigen reference ranges: population specific. J Urol. 1998. 159:444–448.

17. Ito K, Yamamoto T, Kubota Y, Suzuki K, Fukabori Y, Kurokawa K, et al. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology. 2000. 56:278–282.

18. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000. 56:255–260.

19. Wolff JM, Brehmer B, Borchers H, Rohde D, Jakse G. Are age-specific reference ranges for prostate specific antigen population specific? Anticancer Res. 2000. 20:4981–4983.

20. Wu TT, Huang JK. The clinical usefulness of prostate-specific antigen (PSA) level and age-specific PSA reference ranges for detecting prostate cancer in Chinese. Urol Int. 2004. 72:208–211.

21. Park HK, Byun SS, Sohn DW, Hong SK, Lee E, Lee SE, et al. The efficacy of 12-site biopsy protocol in men with elevated serum prostate-specific antigen level only. Korean J Urol. 2005. 46:463–466.

22. Kobayashi T, Nishizawa K, Ogura K, Mitsumori K, Ide Y. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0ng/ml equivalent to that in men with 4.1 to 10.0ng/ml in a Japanese population. Urology. 2004. 63:727–731.

23. Bassler TJ, Orozco R, Bassler IC, O'Dowd GJ, Stamey TA. Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant. Urology. 1998. 52:1064–1069.

24. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993. 71:933–938.

25. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate. 2006. 66:1285–1291.

26. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003. 289:1414–1420.